Namely, Viking is in the early stages of a new clinical effort focusing on a dual agonist featuring the amylin and calcitonin ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Keybioscience AG and Eli Lilly & Co. have agreed to extend their collaboration on the development of dual amylin and calcitonin receptor agonists (DACRAs), a new class of potential treatments for ...

This program uses two mechanisms of action, targeting the amylin and calcitonin receptors, which are not represented elsewhere in its pipeline so far. That means it isn't just a rehash of its other ...

In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity treatments. Takeda paid the San Diego–based biotech $75 million ...

According to revised terms of the deal announced Thursday, the Indiana-based drugmaker will own global rights to KeyBioscience’s platform, designed to develop Dual Amylin Calcitonin Receptor ...

Lilly will expand its rights to the dual amylin calcitonin receptor agonists (DACRA) platform of KeyBioscience to develop ...

Also during the second quarter, Viking announced in vivo results from a series of internally developed dual agonist of the amylin and calcitonin receptors. These compounds demonstrated body weight ...

Miacalcin is a form of calcitonin which is a hormone that we produce in the body. Calcitonin slows down our bone losses so that our own bone building can get caught up and even increase bone density.